Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 259 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Experts Urge to Remove Care Inequalities for Adolescents and Young Adults... April 8, 2021 Answers to Your Questions About Sunscreen Ingredients April 21, 2022 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 ESMO Advocates for Equal Access to Optimal Cancer Care for all... May 18, 2026 Load more HOT NEWS The Recently Leaked Secret to Marijuana News Discovered FDA Approves Second CAR T-Cell Therapy for Lymphoma Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... ESMO Breast Cancer Virtual Congress 2021, 5-8 May
